Document Detail

Action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) against untreated human ovarian cancers in the murine xenograft assay.
MedLine Citation:
PMID:  4007612     Owner:  NLM     Status:  MEDLINE    
The activity of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) was determined in nine untreated human ovarian cancer specimens, using the murine subrenal capsule xenograft assay. Tumor cytotoxic effect was demonstrated in seven out of the nine tumors implanted. The drug was well tolerated by the test animals. Tiazofurin may prove to be an effective chemotherapeutic agent in the treatment of ovarian cancer.
J P Micha; P R Kucera; C U Preve; M A Rettenmaier; J A Stratton; P J DiSaia
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Gynecologic oncology     Volume:  21     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  1985 Jul 
Date Detail:
Created Date:  1985-08-02     Completed Date:  1985-08-02     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  351-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Mice, Inbred Strains
Neoplasm Transplantation
Ovarian Neoplasms / drug therapy*
Ribavirin / analogs & derivatives,  therapeutic use*
Ribonucleosides / therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ribonucleosides; 36791-04-5/Ribavirin; 60084-10-8/tiazofurin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Establishment of a new ovarian tumor line in nude mice and its application to treatment of the donor...
Next Document:  Bromocriptine in the treatment of carcinoma of the cervix: a phase II trial.